BCEL Stock Price, Atreca Inc Quote, Chart

Market Summary

USD0.090.00

Market Closed

0.00%

BCEL Stock Price

View Fullscreen

BCEL RSI Chart

BCEL Valuation

Market Cap

3.1M

Price/Earnings (Trailing)

-0.03

EV/EBITDA

0.11

Price/Free Cashflow

-0.05

MarketCap/EBT

-0.03

BCEL Price/Sales (Trailing)

BCEL Profitability

Return on Equity

-908.6%

Return on Assets

-371.1%

Free Cashflow Yield

-2.1K%

BCEL Fundamentals

BCEL Earnings

Earnings (TTM)

-97.8M

Earnings Growth (Yr)

-57.05%

Earnings Growth (Qtr)

-88.76%

Breaking Down BCEL Revenue

Last 30 days

12.5%

Last 90 days

-67.9%

Trailing 12 Months

-90.5%

How does BCEL drawdown profile look like?

BCEL Financial Health

Current Ratio

1.58

BCEL Investor Care

Shares Dilution (1Y)

1.64%

Diluted EPS (TTM)

-2.5

Tracking the Latest Insider Buys and Sells of Atreca Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 11, 2024	orwin john a	bought	0.01	0.01	1.00	president & ceo
Apr 01, 2024	serafini tito	sold	-1,455	0.07	-20,788	-
Oct 19, 2023	baker bros. advisors lp	sold	-110,582	0.4025	-274,739	-
Sep 01, 2023	serafini tito	sold	-3,144	0.3746	-8,393	-
Sep 01, 2023	orwin john a	sold	-8,597	0.3746	-22,951	president & ceo
Sep 01, 2023	courtney phillips	sold	-2,645	0.3746	-7,061	general counsel & secretary
Aug 02, 2023	gould stephen e	sold	-3,881	0.9522	-4,076	chief scientific officer
Aug 02, 2023	courtney phillips	sold	-3,881	0.9522	-4,076	general counsel & secretary
Aug 02, 2023	cross herb	sold	-5,224	0.9522	-5,487	chief financial officer
Aug 02, 2023	serafini tito	sold	-5,224	0.9522	-5,487	chief strategy officer

Which funds bought or sold BCEL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-2,000	-	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-99.00	-	-	-%
Apr 16, 2024	TSFG, LLC	sold off	-100	-	-	-%
Apr 15, 2024	PFS Partners, LLC	sold off	-100	-263	-	-%
Apr 12, 2024	DLK Investment Management, LLC	sold off	-100	-11,748	-	-%
Apr 05, 2024	CWM, LLC	unchanged	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-31.58	-226,821	120,028	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	30.66	-6,210	12,100	-%
Feb 27, 2024	Beaird Harris Wealth Management, LLC	sold off	-100	-21.00	-	-%
Feb 15, 2024	BARCLAYS PLC	unchanged	-	-6,000	6,000	-%

Are Funds Buying or Selling BCEL?

Are funds buying BCEL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BCEL

No. of Funds

Unveiling Atreca Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 10, 2024	baker bros. advisors lp	19.99%	7,677,982	SC 13G
Dec 07, 2022	blackrock inc.	4.4%	1,428,514	SC 13G/A
Feb 14, 2022	redmile group, llc	2.6%	800,306	SC 13G/A
Feb 14, 2022	boxer capital, llc	7.2%	2,202,333	SC 13G/A
Feb 14, 2022	ecor1 capital, llc	0%	0	SC 13G/A
Feb 14, 2022	ecor1 capital, llc	0%	0	SC 13G/A
Feb 03, 2022	blackrock inc.	9.7%	2,951,287	SC 13G/A
Dec 10, 2021	wellington management group llp	4.27%	1,300,000	SC 13G/A
Nov 15, 2021	logos global management lp	3.3%	996,584	SC 13G
Aug 09, 2021	blackrock inc.	10.2%	3,071,861	SC 13G/A

Recent SEC filings of Atreca Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	DEFM14A	DEFM14A
Apr 17, 2024	4	Insider Trading
Apr 11, 2024	PREM14A	PREM14A
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 01, 2024	S-8 POS	Employee Benefits Plan
Apr 01, 2024	15-12G	15-12G
Apr 01, 2024	S-8 POS	Employee Benefits Plan

Peers (Alternatives to Atreca Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	5.56%	-15.17%	-9.03	6.22	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.9B	1.8B	-2.25%	-24.69%	-42.88	10.32	76.23%	61.08%
BMRN	15.8B	2.5B	-4.35%	-11.20%	76.99	6.4	13.74%	186.89%
INCY	11.9B	3.8B	-6.50%	-24.30%	15.95	3.16	8.58%	129.81%
MID-CAP
APLS	5.6B	396.6M	-22.91%	-44.64%	-10.5	14	425.83%	18.94%
BBIO	4.8B	-	-9.87%	93.55%	-7.27	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-2.73%	5.06%	-14.83	13.11	440.80%	-27.84%
ARWR	2.9B	240.7M	-18.02%	-34.57%	-9.66	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.68%	-20.30%	-45.81	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.49%	-8.60%	25.07	4.5	85.90%	-14.05%
NVAX	652.2M	983.7M	0.22%	-33.81%	-1.2	0.66	-50.36%	17.16%
CRBP	390.9M	881.7K	-1.95%	364.46%	-8.76	466.16	-77.61%	-5.33%
INO	270.2M	4.9M	-11.89%	28.44%	-2	55.51	-54.97%	51.71%
IBIO	6.4M	2.1M	-44.78%	68.18%	-0.24	2.14	-13.45%	66.37%

Atreca Inc News

Latest updates

Atreca Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	-77.1%	26.00	115	134	155	172	191	214	200	220	241	262	272	275	165	179	196	213	227	122
Current Assets	-41.2%	25.00	42.00	60.00	78.00	93.00	110	123	122	162	193	225	249	264	149	154	176	206	222	117
Cash Equivalents	-51.3%	13.00	28.00	39.00	31.00	22.00	28.00	50.00	96.00	115	95.00	91.00	62.00	135	102	93.00	159	167	156	115
Net PPE	-95.5%	2.00	35.00	37.00	38.00	40.00	41.00	42.00	43.00	44.00	45.00	34.00	20.00	8.00	8.00	7.00	6.00	5.00	4.00	4.00
Liabilities	-77.9%	16.00	70.00	73.00	77.00	76.00	76.00	76.00	45.00	45.00	42.00	40.00	30.00	14.00	10.00	9.00	9.00	8.00	8.00	5.00
Current Liabilities	29.8%	16.00	12.00	14.00	16.00	15.00	13.00	13.00	17.00	16.00	14.00	19.00	17.00	9.00	7.00	7.00	8.00	8.00	8.00	5.00
Shareholder's Equity	-75.9%	11.00	45.00	61.00	78.00	96.00	115	138	155	175	199	221	242	261	154	170	187	205	219	-
Retained Earnings	-7.3%	-533	-497	-477	-456	-435	-412	-384	-359	-330	-302	-276	-250	-227	-204	-184	-164	-143	-128	-96.62
Additional Paid-In Capital	0.4%	544	542	539	536	532	528	523	515	506	501	498	492	489	358	354	351	349	347	4.00
Shares Outstanding	0.6%	39.00	39.00	39.00	39.00	39.00	39.00	38.00	37.00	37.00	37.00	37.00	32.00	30.00	28.00	28.00	16.00	12.00	5.00	2.00
Float	-	-	-	-	-	-	49.00	-	-	-	198	-	-	-	305	-	-	-	211	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	4.3%	-17,216	-17,984	-14,444	-15,433	-16,360	-23,377	-25,551	-16,106	-16,053	-11,063	-17,698	-18,097	-14,979	-15,681	-17,914	-16,219	-15,591	-13,751	-12,977	-	-
Share Based Compensation	-19.8%	2,297	2,863	3,223	3,183	3,884	5,488	4,336	4,741	3,853	3,882	4,400	3,123	3,487	3,384	2,482	2,043	1,878	1,359	776	-	-
Cashflow From Investing	-51.6%	2,991	6,185	23,000	25,349	10,329	1,259	-24,389	-6,710	35,298	14,741	45,908	-54,625	-78,785	23,215	-48,800	7,986	29,467	9,071	-74,428	-	-
Cashflow From Financing	800.0%	9.00	1.00	109	-	145	-9.00	3,767	4,373	341	19.00	713	439	126,963	526	943	43.00	-2,133	133,320	-56.00	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BCEL Income Statement

2023-09-30

Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Statements of Operations - USD ($) $ in Thousands	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Expenses
Research and development	$ 10,407	$ 16,045	$ 36,774	$ 53,062
General and administrative	5,386	7,247	20,300	23,930
Restructuring and impairment charges	20,856		20,856
Total expenses	36,649	23,292	77,930	76,992
Interest and other income (expense)
Other income	80		243	750
Interest income	354	233	1,276	430
Net other income (expense)	434	233	1,519	1,180
Loss before income tax expense	(36,215)	(23,059)	(76,411)	(75,812)
Net loss	$ (36,215)	$ (23,059)	$ (76,411)	$ (75,812)
Net loss per share, basic (in dollars per share)	$ (0.92)	$ (0.60)	$ (1.95)	$ (1.97)
Net loss per share, diluted (in dollars per share)	$ (0.92)	$ (0.60)	$ (1.95)	$ (1.97)
Weighted-average shares used in computing net loss per share, basic (in shares)	39,354,502	38,720,575	39,202,045	38,434,327
Weighted-average shares used in computing net loss per share, diluted (in shares)	39,354,502	38,720,575	39,202,045	38,434,327

BCEL Balance Sheet

2023-09-30

Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 13,470	$ 30,819
Investments	7,918	39,676
Prepaid expenses and other current assets	3,305	7,531
Total current assets	24,693	78,026
Property and equipment, net	1,614	37,972
Operating lease right-of-use assets		36,056
Deposits and other	35	2,976
Total assets	26,342	155,030
Current Liabilities
Accounts payable	4,062	1,741
Accrued expenses	9,292	9,681
Operating lease liabilities, current portion	1,281	3,544
Other current liabilities	948	1,327
Total current liabilities	15,583	16,293
Operating lease liabilities, net of current portion		60,331
Total liabilities	15,583	76,624
Commitment and contingencies (Note 9)
Stockholders' equity
Additional paid-in capital	544,094	535,592
Accumulated other comprehensive loss	(4)	(266)
Accumulated deficit	(533,335)	(456,924)
Total stockholders' equity	10,759	78,406
Total liabilities and stockholders' equity	26,342	155,030
Class A common stock
Stockholders' equity
Common stock	3	3
Class B common stock
Stockholders' equity
Common stock	$ 1	$ 1

About Atreca Inc

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

CEO	Mr. John A. Orwin M.B.A.
WEBSITE	atreca.com
INDUSTRY	Biotechnology
EMPLOYEES	90

Atreca Inc Frequently Asked Questions

What is the ticker symbol for Atreca Inc? What does BCEL stand for in stocks?

BCEL is the stock ticker symbol of Atreca Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Atreca Inc (BCEL)?

As of Wed May 01 2024, market cap of Atreca Inc is 3.15 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BCEL stock?

You can check BCEL's fair value in chart for subscribers.

What is the fair value of BCEL stock?

You can check BCEL's fair value in chart for subscribers. The fair value of Atreca Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Atreca Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BCEL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Atreca Inc a good stock to buy?

The fair value guage provides a quick view whether BCEL is over valued or under valued. Whether Atreca Inc is cheap or expensive depends on the assumptions which impact Atreca Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCEL.